Large-scale testing (Phase 3)Study completedNCT02046616
What this trial is testing
Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 133